There is growing interest in the potential and use of extracellular vesicles (EVs) for a range of diagnostic and therapeutic applications. EVs have
been shown, in some instances, to mediate the regenerative effects elicited by stem cell therapies. As such, they are being studied to identify the
extent to which these extracellular bodies can be employed as a therapeutic entity, and significant R&D activity is underway to further understand their clinical and commercial potential. However, successful translation will first require further characterization and standardization of EV
production, as well as addressing some of the major challenges associated
with their reproducible manufacture. This includes the capacity to produce EVs at a scale that is both clinically and commercially effective. This
article will highlight some of the bioprocessing and manufacturing considerations and challenges associated with the standardized production
of EVs.
History
School
Sport, Exercise and Health Sciences
Published in
Cell and Gene Therapy Insights
Volume
3
Issue
6
Pages
683 - 694
Citation
DAVIES, O.G. and RAFIQ, Q.A., 2017. Considerations for the bioprocessing, manufacture and translation of extracellular vesicles for therapeutic and diagnostic applications. Cell and Gene Therapy Insights, 3(6), pp. 683 - 694.
Publisher
BioInsights Publishing, Ltd.
Version
VoR (Version of Record)
Publisher statement
This work is made available according to the conditions of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) licence. Full details of this licence are available at: https://creativecommons.org/licenses/by-nc-nd/4.0/
Publication date
2017-11-20
Notes
This is an Open Access Article. It is published by BioInsights Publishing, Ltd. under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) licence. Full details of this licence are available at: https://creativecommons.org/licenses/by-nc-nd/4.0/